There is emerging evidence that ZnO-NPs can stimulate an immunogenic form of tumor cell death (via pathways like cGAS-STING), suggesting a potential role in cancer immunotherapy when used in combination with other agents, beyond chemotherapeutics [5,46]. This evidence concerns the gene STING1 and neoplasm.